$ATYR
aTyr Pharma Inc

2024 Q3 Form 10-Q Financial Statement

#000095017024096185 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.342M
YoY Change -10.16%
% of Gross Profit
Research & Development $13.97M
YoY Change 42.0%
% of Gross Profit
Depreciation & Amortization $177.0K
YoY Change 9.94%
% of Gross Profit
Operating Expenses $17.32M
YoY Change 27.71%
Operating Profit -$17.32M
YoY Change 27.71%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.009M
YoY Change -17.02%
Pretax Income -$16.31M
YoY Change 32.14%
Income Tax
% Of Pretax Income
Net Earnings -$16.30M
YoY Change 32.52%
Net Earnings / Revenue
Basic Earnings Per Share -$0.23
Diluted Earnings Per Share -$0.23
COMMON SHARES
Basic Shares Outstanding 75.80M 69.01M
Diluted Shares Outstanding 72.28M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $78.48M
YoY Change -27.72%
Cash & Equivalents $6.805M
Short-Term Investments $71.68M
Other Short-Term Assets $10.19M
YoY Change 123.25%
Inventory
Prepaid Expenses $10.19M
Receivables
Other Receivables $1.628M
Total Short-Term Assets $90.30M
YoY Change -21.09%
LONG-TERM ASSETS
Property, Plant & Equipment $5.184M
YoY Change -10.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $130.0K
YoY Change 80.56%
Total Long-Term Assets $15.64M
YoY Change -14.6%
TOTAL ASSETS
Total Short-Term Assets $90.30M
Total Long-Term Assets $15.64M
Total Assets $105.9M
YoY Change -20.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.255M
YoY Change 143.22%
Accrued Expenses $9.409M
YoY Change -12.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $517.0K
YoY Change 16.7%
Total Short-Term Liabilities $11.84M
YoY Change -4.29%
LONG-TERM LIABILITIES
Long-Term Debt $1.164M
YoY Change -23.67%
Other Long-Term Liabilities $11.51M
YoY Change -10.06%
Total Long-Term Liabilities $12.68M
YoY Change -11.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.84M
Total Long-Term Liabilities $12.68M
Total Liabilities $24.33M
YoY Change -8.22%
SHAREHOLDERS EQUITY
Retained Earnings -$499.8M
YoY Change 13.1%
Common Stock $76.00K
YoY Change 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $81.61M
YoY Change
Total Liabilities & Shareholders Equity $105.9M
YoY Change -20.19%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$16.30M
YoY Change 32.52%
Depreciation, Depletion And Amortization $177.0K
YoY Change 9.94%
Cash From Operating Activities -$20.45M
YoY Change 70.27%
INVESTING ACTIVITIES
Capital Expenditures $8.000K
YoY Change -99.67%
Acquisitions
YoY Change
Other Investing Activities $6.736M
YoY Change -482.51%
Cash From Investing Activities $6.728M
YoY Change -261.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.40M
YoY Change 67.12%
NET CHANGE
Cash From Operating Activities -20.45M
Cash From Investing Activities 6.728M
Cash From Financing Activities 13.40M
Net Change In Cash -321.0K
YoY Change -96.06%
FREE CASH FLOW
Cash From Operating Activities -$20.45M
Capital Expenditures $8.000K
Free Cash Flow -$20.46M
YoY Change 42.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001339970
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://www.atyrpharma.com/20240630#LicenseAndCollaborationRevenuesMember
CY2023Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://www.atyrpharma.com/20240630#LicenseAndCollaborationRevenuesMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://www.atyrpharma.com/20240630#LicenseAndCollaborationRevenuesMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://www.atyrpharma.com/20240630#LicenseAndCollaborationRevenuesMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37378
dei Entity Registrant Name
EntityRegistrantName
ATYR PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3435077
dei Entity Address Address Line1
EntityAddressAddressLine1
10240 Sorrento Valley
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
731-8389
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
ATYR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
75796198
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6805000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22544000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
71677000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
75622000
CY2024Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1628000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2436000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10187000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2390000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
90297000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
102992000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2896000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3484000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5184000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5531000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5942000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6727000
CY2024Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1490000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1788000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
130000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131000
CY2024Q2 us-gaap Assets
Assets
105939000
CY2023Q4 us-gaap Assets
Assets
120653000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1255000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3529000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9409000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11559000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
656000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
831000
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
517000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
497000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11837000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16416000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11514000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12339000
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1164000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1428000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75796198
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75796198
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63286404
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63286404
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
76000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
63000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
581520000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
558692000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-168000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-74000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-499820000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-468023000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
81608000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
90658000
CY2024Q2 us-gaap Minority Interest
MinorityInterest
-184000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-188000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
81424000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
90470000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105939000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120653000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
235000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
235000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13973000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9840000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27337000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19219000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3342000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3718000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6849000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7126000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
17315000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
13558000
us-gaap Operating Expenses
OperatingExpenses
34186000
us-gaap Operating Expenses
OperatingExpenses
26345000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17315000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13558000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33951000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26345000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1009000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1216000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2158000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2051000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-16306000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-12342000
us-gaap Profit Loss
ProfitLoss
-31793000
us-gaap Profit Loss
ProfitLoss
-24294000
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-16306000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12338000
us-gaap Net Income Loss
NetIncomeLoss
-31797000
us-gaap Net Income Loss
NetIncomeLoss
-24289000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72284351
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72284351
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55143805
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55143805
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69204401
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69204401
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48557347
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48557347
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-16306000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-12342000
us-gaap Profit Loss
ProfitLoss
-31793000
us-gaap Profit Loss
ProfitLoss
-24294000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-85000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-94000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
100000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-16316000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-12427000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-31887000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-24194000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-4000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
4000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-5000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16316000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12423000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31891000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24189000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
90470000
CY2024Q1 atyr Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
8643000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
740000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-84000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-15487000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
84282000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
39000
CY2024Q2 atyr Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
12692000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
727000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-16306000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
81424000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71284000
CY2023Q1 atyr Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1489000
CY2023Q1 atyr Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs
IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
48073000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
619000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
185000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-11952000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109698000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
65000
CY2023Q2 atyr Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
8058000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
658000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-85000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-12342000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
106052000
us-gaap Profit Loss
ProfitLoss
-31793000
us-gaap Profit Loss
ProfitLoss
-24294000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
355000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
241000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1467000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1277000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1546000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1301000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
798000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1100000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
13000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-510000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-10554000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7796000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1492000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4407000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1019000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-417000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
2347000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42829000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12600000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3641000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
40127000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
68702000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
45524000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
30000000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
15000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5372000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42328000
atyr Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
39000
atyr Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
65000
atyr Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
21335000
atyr Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
9547000
atyr Proceeds From Issuance Of Common Stock Through Underwritten Follow On Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughUnderwrittenFollowOnOfferingNetOfOfferingCosts
0
atyr Proceeds From Issuance Of Common Stock Through Underwritten Follow On Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughUnderwrittenFollowOnOfferingNetOfOfferingCosts
48073000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
244000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
171000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21130000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57514000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16327000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2586000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26028000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13146000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9701000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15732000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6805000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12313000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2896000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3419000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9701000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15732000
us-gaap Interest Paid Net
InterestPaidNet
74000
us-gaap Interest Paid Net
InterestPaidNet
94000
atyr Purchases Of Property And Equipment In Accounts Payable
PurchasesOfPropertyAndEquipmentInAccountsPayable
34000
atyr Purchases Of Property And Equipment In Accounts Payable
PurchasesOfPropertyAndEquipmentInAccountsPayable
548000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1938000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-16300000
us-gaap Net Income Loss
NetIncomeLoss
-31800000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-499800000
CY2024Q2 atyr Cash And Cash Equivalents Restricted Cash And Available For Sale Investments
CashAndCashEquivalentsRestrictedCashAndAvailableForSaleInvestments
81400000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2900000
CY2023 atyr Employee Retention Of Payroll Expenses
EmployeeRetentionOfPayrollExpenses
1200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unaudited interim condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our unaudited interim condensed consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure for these items in our unaudited interim condensed consolidated financial statements and accompanying notes. The most significant estimates in our unaudited interim condensed consolidated financial statements relate to clinical trial and research and development expenses. Although these estimates are based on our knowledge of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">current </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5893090
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4078208
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
71795000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
119000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
71677000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
75646000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
52000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
76000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
75622000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
25
CY2024Q2 atyr Available For Sale Investments Number Of Positions
AvailableForSaleInvestmentsNumberOfPositions
27
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
4
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
8000000
CY2024Q2 atyr Debt Securities Available For Sale Accrued Interest
DebtSecuritiesAvailableForSaleAccruedInterest
300000
CY2023Q4 atyr Debt Securities Available For Sale Accrued Interest
DebtSecuritiesAvailableForSaleAccruedInterest
300000
CY2022Q2 us-gaap Area Of Land
AreaOfLand
23696
atyr Lessee Operating Lease Lease Commencement Date
LesseeOperatingLeaseLeaseCommencementDate
2023-03-20
CY2023Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P124M
us-gaap Lessee Operating Lease Lease Not Yet Commenced Option To Extend
LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend
We also have one option to extend the Lease Term for five years.
CY2022Q2 us-gaap Lessee Operating Lease Lease Not Yet Commenced Existence Of Option To Extend
LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend
true
CY2022Q2 us-gaap Lessee Operating Lease Lease Not Yet Commenced Renewal Term1
LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
P5Y
CY2022Q2 atyr Base Rent Per Square Foot
BaseRentPerSquareFoot
5.75
CY2022Q2 atyr Annual Upward Adjustments On Base Rate Percentage
AnnualUpwardAdjustmentsOnBaseRatePercentage
0.03
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
5300000
CY2023Q2 us-gaap Area Of Land
AreaOfLand
1500
CY2024Q2 us-gaap Area Of Land
AreaOfLand
1170
CY2024Q2 us-gaap Area Of Land
AreaOfLand
24866
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
842000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1722000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1780000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1916000
CY2024Q2 atyr Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
11812000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5902000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12170000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
656000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11514000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.088
CY2024Q2 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P48M
CY2024Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
317000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
634000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
676000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
264000
CY2024Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
210000
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
1681000
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
517000
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1164000
CY2024Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2024Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.083
CY2022Q2 atyr Commission Rate Equal To Gross Proceeds1
CommissionRateEqualToGrossProceeds1
0.03
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11748798
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3956827
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1903498
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
48360
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.45
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5811965
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.55
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
727000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
658000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1467000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1277000

Files In Submission

Name View Source Status
0000950170-24-096185-index-headers.html Edgar Link pending
0000950170-24-096185-index.html Edgar Link pending
0000950170-24-096185.txt Edgar Link pending
0000950170-24-096185-xbrl.zip Edgar Link pending
atyr-20240630.htm Edgar Link pending
atyr-20240630.xsd Edgar Link pending
atyr-ex31_1.htm Edgar Link pending
atyr-ex31_2.htm Edgar Link pending
atyr-ex32_1.htm Edgar Link pending
atyr-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
atyr-20240630_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending